
Sign up to save your podcasts
Or


Jennifer Quint, Thorax’s Journal Club editor, talks to David Jablons, University of California San Francisco, and consultant for Life Technologies, about his assay to predict survival in resected non-squamous, non-small-cell lung cancer.
See also:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2961941-7/abstract
By BMJ Group4
11 ratings
Jennifer Quint, Thorax’s Journal Club editor, talks to David Jablons, University of California San Francisco, and consultant for Life Technologies, about his assay to predict survival in resected non-squamous, non-small-cell lung cancer.
See also:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2961941-7/abstract

137 Listeners

317 Listeners

498 Listeners

35 Listeners

48 Listeners

5 Listeners

7 Listeners

5 Listeners

3 Listeners

3 Listeners

7 Listeners

9 Listeners

40 Listeners

14 Listeners

1 Listeners

50 Listeners

0 Listeners

6 Listeners

883 Listeners

16 Listeners

3 Listeners

3 Listeners

22 Listeners

1,145 Listeners

195 Listeners

23 Listeners

367 Listeners

426 Listeners

2,089 Listeners

272 Listeners

0 Listeners